Genetic instability influences drug response in cancer cells

Current Drug Targets

Volumn 11, Issue 10, 2010, Pages 1317-1324

  Damia, G ^a   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Colon cancer; Microsatellite instability; Mismatch repair; Response to therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CAMPTHOTECIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; IRINOTECAN; MERCAPTOPURINE; METHYLNITROSOUREA; N METHYL N NITROSOGUANIDINE; OXALIPLATIN; PROCARBAZINE; TEMOZOLOMIDE; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN CANCER; CANCER CELL; CANCER RISK; CELL CYCLE; COLORECTAL CANCER; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIUM CANCER; GENE MUTATION; GENOMIC INSTABILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN CELL; KIDNEY CANCER; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PROGNOSIS; STOMACH CANCER;

EID: 77957988512     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450111007011317     Document Type: Article

References (113)

1. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009; 361: 1475-85.
2. Hoeijmakers JH. Genome maintenance mechanisms for preventingcancer. Nature 2001; 411: 366-74.
3. Jackson SP, Bartek J. The DNA-damage response in humanbiology and disease. Nature 2009; 461: 1071-8.
4. Martin SA, Hewish M, Lord CJ, et al. Genomic instability and the selection of treatments for cancer. J Pathol 220: 281-9.
5. Risinger MA, Groden J. Crosslinks and crosstalk: human cancersyndromes and DNA repair defects. Cancer Cell 2004; 6: 539-45.
6. Bartek J, Bartkova J, Lukas J. DNA damage signalling guardsagainst activated oncogenes and tumour progression. Oncogene 2007; 26: 7773-9.
7. Kennedy RD, D'Andrea AD. DNA repair pathways in clinicalpractice: lessons from pediatric cancer susceptibility syndromes. JClin Oncol 2006; 24: 3799-808.
8. Bartek J, Lukas J. DNA damage checkpoints: from initiation torecovery or adaptation. Curr Opin Cell Biol 2007; 19: 238-45.
9. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditionalhaploinsufficiency'. Cell Cycle 2007; 6: 2344-7.
10. Darzynkiewicz Z, Traganos F, Wlodkowic D. Impaired DNA damage response-an Achilles' heel sensitizing cancer tochemotherapy and radiotherapy. Eur J Pharmacol 2009; 625: 143-50.
11. Powell SN, Bindra RS. Targeting the DNA damage response forcancer therapy. DNA Repair (Amst) 2009; 8: 1153-65.
12. Imai K, Yamamoto H. Carcinogenesis and microsatelliteinstability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008; 29: 673-80.
13. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities inhuman cancers. Nature 1998; 396: 643-9.
14. Duker NJ. Chromosome breakage syndromes and cancer. Am JMed Genet 2002; 115: 125-9.
15. Charames GS, Bapat B. Genomic instability and cancer. Curr MolMed 2003; 3: 589-96.
16. Ricke RM, van Ree JH, van Deursen JM. Whole chromosomeinstability and cancer: a complex relationship. Trends Genet 2008;24: 457-66.
17. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpointgenes in human cancers. Nature 1998; 392: 300-3.
18. Draviam VM, Xie S, Sorger PK. Chromosome segregation andgenomic stability. Curr Opin Genet Dev 2004; 14: 120-5.
19. Sieber OM, Heinimann K, Tomlinson IP. Genomic instability-theengine of tumorigenesis? Nat Rev Cancer 2003; 3: 701-8.
20. Cleaver JE, Lam ET, Revet I. Disorders of nucleotide excisionrepair: the genetic and molecular basis of heterogeneity. Nat RevGenet 2009; 10: 756-68.
21. Schneider J, Classen V, Helmig S. XRCC1 polymorphism and lungcancer risk. Expert Rev Mol Diagn 2008; 8: 761-80.
22. Hopkins J, Cescon DW, Tse D, et al. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer EpidemiolBiomarkers Prev 2008; 17: 490-9.
23. Tudek B. Base excision repair modulation as a risk factor forhuman cancers. Mol Aspects Med 2007; 28: 258-75.
24. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for themaintenance of genome integrity. Nat Rev Mol Cell Biol 11: 138-48.
25. Saeki T, Ouchi M, Ouchi T. Physiological and oncogenic Aurora-Apathway. Int J Biol Sci 2009; 5: 758-62.
26. Vader G, Lens SM. The Aurora kinase family in cell division andcancer. Biochim Biophys Acta 2008; 1786: 60-72.
27. Jiricny J. The multifaceted mismatch-repair system. Nat Rev MolCell Biol 2006; 7: 335-46.
28. Li GM. Mechanisms and functions of DNA mismatch repair. CellRes 2008; 18: 85-98.
29. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005; 74: 681-710.
30. Harfe BD, Jinks-Robertson S. DNA mismatch repair and geneticinstability. Annu Rev Genet 2000; 34: 359-99.
31. Harfe BD, Jinks-Robertson S. Mismatch repair proteins and mitoticgenome stability. Mutat Res 2000; 451: 151-67.
32. Hoffmann ER, Borts RH. Meiotic recombination intermediates andmismatch repair proteins. Cytogenet Genome Res 2004; 107: 232-48.
33. Rayssiguier C, Thaler DS, Radman M. The barrier to recom-bination between Escherichia coli and Salmonella typhimurium isdisrupted in mismatch-repair mutants. Nature 1989; 342: 396-401.
34. Shah SN, Hile SE, Eckert KA. Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancerphenotypes. Cancer Res 70: 431-5.
35. Laghi L, Bianchi P, Malesci A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 2008; 27: 6313-21.
36. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type IITGF-beta receptor in colon cancer cells with microsatelliteinstability. Science 1995; 268: 1336-8.
37. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshiftmutations in the BAX gene in colon cancers of the microsatellitemutator phenotype. Science 1997; 275: 967-9.
38. Souza RF, Appel R, Yin J, et al. Microsatellite instability in theinsulin-like growth factor II receptor gene in gastrointestinaltumours. Nat Genet 1996; 14: 255-7.
39. Malkhosyan S, Rampino N, Yamamoto H, et al. Frameshiftmutator mutations. Nature 1996; 382: 499-500.
40. Umar A, Boland CR, Terdiman JP, et al. Revised BethesdaGuidelines for hereditary nonpolyposis colorectal cancer (Lynchsyndrome) and microsatellite instability. J Natl Cancer Inst 2004;96: 261-8.
41. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7: 153-62.
42. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancerdetection and familial predisposition: development of international criteria for the determination of microsatellite instability incolorectal cancer. Cancer Res 1998; 58: 5248-57.
43. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009;16: 405-17.
44. Blanes A, Diaz-Cano SJ. Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas. World J Gastroenterol 2006; 12: 5932-40.
45. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A NationalCancer Institute Workshop on Hereditary Nonpolyposis ColorectalCancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758-62.
46. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria forhereditary nonpolyposis colorectal cancer (HNPCC, Lynchsyndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-6.
47. Salovaara R, Loukola A, Kristo P, et al. Population-basedmolecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18: 2193-200.
48. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditarynonpolyposis colorectal cancer and the feasibility of molecularscreening for the disease. N Engl J Med 1998; 338: 1481-7.
49. Perucho M. Tumors with microsatellite instability: manymutations, targets and paradoxes. Oncogene 2003; 22: 2223-5.
50. Karamurzin Y, Rutgers JK. DNA mismatch repair deficiency inendometrial carcinoma. Int J Gynecol Pathol 2009; 28: 239-55.
51. Greenson JK, Bonner JD, Ben-Yzhak O, et al. Phenotype ofmicrosatellite unstable colorectal carcinomas: Well-differentiatedand focally mucinous tumors and the absence of dirty necrosiscorrelate with microsatellite instability. Am J Surg Pathol 2003; 27:563-70.
52. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instabilityand clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
53. Kochhar R, Halling KC, McDonnell S, et al. Allelic imbalance andmicrosatellite instability in resected Duke's D colorectal cancer. Diagn Mol Pathol 1997; 6: 78-84.
54. Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood ofmetastases in patients with microsatellite-unstable colorectalcancer. Clin Cancer Res 2007; 13: 3831-9.
55. Jiricny J. Replication errors: cha(lle)nging the genome. EMBO J 1998; 17: 6427-36.
56. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair indrug resistance. Clin Cancer Res 1998; 4: 1-6.
57. Karran P. Mechanisms of tolerance to DNA damaging therapeuticdrugs. Carcinogenesis 2001; 22: 1931-7.
58. Bignami M, Casorelli I, Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer 2003; 39:2142-9.
59. Valentini AM, Armentano R, Pirrelli M, et al. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer Treat Rev 2006; 32: 607-18.
60. Boyer JC, Umar A, Risinger JI, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 1995; 55: 6063-70.
61. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damagesignalling. DNA Repair (Amst) 2004; 3: 1091-101.
62. Yan T, Berry SE, Desai AB, et al. DNA mismatch repair (MMR)mediates 6-thioguanine genotoxicity by introducing single-strandbreaks to signal a G2-M arrest in MMR-proficient RKO cells. ClinCancer Res 2003; 9: 2327-34.
63. Wang JY, Edelmann W. Mismatch repair proteins as sensors ofalkylation DNA damage. Cancer Cell 2006; 9: 417-8.
64. Aquilina G, Ceccotti S, Martinelli S, et al. N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defectivehuman cells. Cancer Res 1998; 58: 135-41.
65. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs inDNA mismatch repair-deficient cells. Clin Cancer Res 1997; 3:1763-7.
66. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase:regulation and importance in response to alkylating carcinogenicand therapeutic agents. Cancer Res 1990; 50: 6119-29.
67. Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 1997; 36:2501-6.
68. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatchrepair in acquired resistance to cisplatin. Cancer Res 1996; 56:3087-90.
69. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance tocisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-5.
70. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the roleof DNA repair pathways. Clin Cancer Res 2008; 14: 1291-5.
71. Rabik CA, Dolan ME. Molecular mechanisms of resistance andtoxicity associated with platinating agents. Cancer Treat Rev 2007;33: 9-23.
72. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-71.
73. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair inplatinum drug resistance. Cancer Res 1996; 56: 4881-6.
74. Sergent C, Franco N, Chapusot C, et al. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are notdefective in DNA mismatch repair proteins. Cancer Chemother Pharmacol 2002; 49: 445-52.
75. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995;270: 21429-32.
76. Fedier A, Schwarz VA, Walt H, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001;93: 571-6.
77. Jacob S, Aguado M, Fallik D, et al. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001; 61: 6555-62.
78. Magrini R, Bhonde MR, Hanski ML, et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1status. Int J Cancer 2002; 101: 23-31.
79. Vilar E, Scaltriti M, Balmana J, et al. Microsatellite instability dueto hMLH1 deficiency is associated with increased cytotoxicity toirinotecan in human colorectal cancer cell lines. Br J Cancer 2008;99: 1607-12.
80. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is apredictive factor of the tumor response to irinotecan in patientswith advanced colorectal cancer. Cancer Res 2003; 63: 5738-44.
81. Giannini G, Rinaldi C, Ristori E, et al. Mutations of an intronicrepeat induce impaired MRE11 expression in primary humancancer with microsatellite instability. Oncogene 2004; 23: 2640-7.
82. Koh KH, Kang HJ, Li LS, et al. Impaired nonhomologous end-joining in mismatch repair-deficient colon carcinomas. Lab Invest 2005; 85: 1130-8.
83. Miquel C, Jacob S, Grandjouan S, et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 2007; 26: 5919-26.
84. Li HR, Shagisultanova EI, Yamashita K, et al. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res 2004; 64: 4760-7.
85. Meyers M, Hwang A, Wagner MW, et al. A role for DNAmismatch repair in sensing and responding to fluoropyrimidinedamage. Oncogene 2003; 22: 7376-88.
86. Meyers M, Wagner MW, Mazurek A, et al. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 2005; 280: 5516-26.
87. Li LS, Morales JC, Hwang A, et al. DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediatedapoptosis. J Biol Chem 2008; 283: 21394-403.
88. Wagner MW, Li LS, Morales JC, et al. Role of c-Abl kinase inDNA mismatch repair-dependent G2 cell cycle checkpoint arrestresponses. J Biol Chem 2008; 283: 21382-93.
89. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact ofmicrosatellite instability and DNA ploidy in human coloncarcinoma patients. Gastroenterology 2006; 131: 729-37.
90. Lanza G, Gafa R, Santini A, et al. Immunohistochemical test forMLH1 and MSH2 expression predicts clinical outcome in stage IIand III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-67.
91. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability insporadic colon cancer is associated with an improved prognosis atthe population level. Cancer Epidemiol Biomarkers Prev 2001; 10:917-23.
92. Popat S, Hubner R, Houlston RS. Systematic review ofmicrosatellite instability and colorectal cancer prognosis. J ClinOncol 2005; 23: 609-18.
93. Roth AD. Stage-specific prognostic value of molecular markers incolon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAMK 60-00 trial. J Clin Oncol 2009; 27: a4002.
94. Sinicrope FA, Rego RL, Garrity-Park MM, et al. Alterations in cellproliferation and apoptosis in colon cancers with microsatelliteinstability. Int J Cancer 2007; 120: 1232-8.
95. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic andpredictive roles of high-degree microsatellite instability in coloncancer: a National Cancer Institute-National Surgical AdjuvantBreast and Bowel Project Collaborative Study. J Clin Oncol 2007;25: 767-72.
96. Lamberti C, Lundin S, Bogdanow M, et al. Microsatelliteinstability did not predict individual survival of unselected patientswith colorectal cancer. Int J Colorectal Dis 2007; 22: 145-52.
97. Black D, Soslow RA, Levine DA, et al. Clinicopathologicsignificance of defective DNA mismatch repair in endometrialcarcinoma. J Clin Oncol 2006; 24: 1745-53.
98. Kauff ND. ATR mutations in endometrial cancer: a window intothe role of mismatch repair defects. J Clin Oncol 2009; 27: 3077-8.
99. Cohn DE, Frankel WL, Resnick KE, et al. Improved survival withan intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 2006; 108: 1208-15.
100. Zighelboim I, Goodfellow PJ, Gao F, et al. Microsatelliteinstability and epigenetic inactivation of MLH1 and outcome ofpatients with endometrial carcinomas of the endometrioid type. JClin Oncol 2007; 25: 2042-8.
101. Zighelboim I, Schmidt AP, Gao F, et al. ATR mutation inendometrioid endometrial cancer is associated with poor clinicaloutcomes. J Clin Oncol 2009; 27: 3091-6.
102. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet 2005;365: 153-65.
103. Lombardi L, Gebbia V, Silvestris N, et al. Adjuvant therapy incolon cancer. Oncology 2009; 77 (Suppl 1): 50-6.
104. Benatti P, Gafa R, Barana D, et al. Microsatellite instability andcolorectal cancer prognosis. Clin Cancer Res 2005; 11: 8332-40.
105. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-basedadjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57.
106. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvantchemotherapy with 5-fluorouracil in colorectal cancer depends onthe mismatch repair status. Eur J Cancer 2009; 45: 365-73.
107. Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site andsex with survival benefit from adjuvant chemotherapy in colorectalcancer. Lancet 2000; 355: 1745-50.
108. Hemminki A, Mecklin JP, Jarvinen H, et al. Microsatelliteinstability is a favorable prognostic indicator in patients withcolorectal cancer receiving chemotherapy. Gastroenterology 2000;119: 921-8.
109. Sargent DL. Confirmatory of deficient mismatch repair (dMMR) asa predicitive marker for lack of benefit from 5-FU basedchemotherapy in stage II and III colon cancer (CC): A pooledmolecular reananlysis of randomized chemotherapy trails. J Clin Oncol 2008: a4008.
110. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy insporadic colon cancer. Nat Rev Clin Oncol 7: 174-7.
111. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatelliteinstability predicts improved response to adjuvant therapy withirinotecan, fluorouracil, and leucovorin in stage III colon cancer:Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27: 1814-21.
112. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracilplus leucovorin is not superior to fluorouracil plus leucovorin aloneas adjuvant treatment for stage III colon cancer: results of CALGB89803. J Clin Oncol 2007; 25: 3456-61.
113. Tejpar S. Microsatellite instability (MSI) in stage II and III cooncancer treated with 5FU-LV or 5FU-LV and iritotecan (PETACC3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 2009; 27:a4001.